Skip to main content

Table 1 Significant historical events related to IgE

From: AllergoOncology: ultra-low IgE, a potential novel biomarker in cancer—a Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI)

Year Name/References Contribution
1869 Bakeley [120] Invented skin tests for allergy diagnosis
1902 Richet and Portier [121] Described the term anaphylaxis
1906 Von Pirquet [122] Used the term “supersensitivity without immunity” to describe symptoms of inhalant allergy and positive skin tests
1913 Clowes [123] Publication of the first successful trial of ragweed subcutaneous immunotherapy
1919 Ramirez [124] Recognized the phenomenon of sensitization, when reporting new horse allergy in a patient who received blood from a horse-allergic donor
1921 Prausnitz and Küstner [120] Described Prausnitz–Küstner (P–K) test, known to sensitize the skin of healthy subjects, through a „transferable sensitization factor“
1930 Coca [125] Introduced the concept of atopy (hereditary tendency to become allergic) and the term “atopic reagin” as the responsible factor
1960+ Fisherman [126]; Mackay [127] First epidemiological studies of allergy and cancer risk
1964 Ogilvie [128] Described reagin-like antibodies in animals immune to helminth parasites
1965, 1967 Johansson et al. [129] A new myeloma protein named IgND found to inhibit P-K activity
1966 Ishizaka [130] Working on an antiserum that could deplete the P-K activity, containing a molecule named γE
1967 Wide et al. [131] RAST (Radio-Allergo Sorbent test) assay development
1968 Bennich et al. [1] Immunoglobulin E discovery announcement
1971 Ishizaka [132] Description of IgE-mediated histamine release
1971 Augustin [133] Published one of the first papers describing IgE levels in cancer and non-cancer patients
1974 Ishizaka and Tomioka [134] First description of IgE-receptors
1992+ Mills et al. [135]; Kallen et al. [136]; Vesterinen et al. [137]; Turner et al. [138] Some first large-scale prospective epidemiological studies of allergy and cancer risk
1999 Gould et al. [139] Reported that IgE antibody-dependent cytotoxicity could be used in suppression of ovarian tumours
1999 Milgrom et al. [140] First randomized placebo-controlled trial using a recombinant humanized monoclonal antibody against IgE (rhuMAb-E25, later named Omalizumab) as treatment in patients with asthma
2005+ Lindelof et al. [141]; Van Hemelrijck M [142] First epidemiological studies of pre-diagnostic IgE levels and total cancer risk
2008+ Jensen-Jarolim et al. [143]; Penichet and Jensen-Jarolim [120]; Platzer [26] Defined the new field of AllergoOncology and the potential mechanisms through which IgE has role in tumour surveillance
2011+ Calboli et al. [22]; Schlehofer et al. [21]; Schwartzbaum et al. [20] First epidemiological studies of pre-diagnostic IgE levels and specific cancer risk
2016 Simpson et al. [144] Dupilumab, a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit, used for treatment in patients with moderate-to-severe atopic dermatitis
2018 Karagiannis SN et al. [145] Initiation of first phase-1 clinical study (NCT02546921) of IgE antibody MOv18 against an ovarian cancer antigen
2019 Ferastraoaru and Rosenstreich [34] First longitudinal study of pre-diagnostic IgE deficiency and cancer risk
2020 Spicer JF et al. [80] Interim data of the first phase-1 clinical study (NCT02546921) of IgE antibody MOv18 against an ovarian cancer antigen presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting